Signal Phase 1 trial shows HIF-2 alpha inhibitor casdatifan produces durable tumor responses in kidney cancer

Summary

Results from a multicenter Phase 1 clinical trial called ARC-20, testing an investigational oral drug named casdatifan in patients with advanced kidney cancer, were announced. Casdatifan is designed to inhibit hypoxia-inducible factor-2 alpha (HIF-2 alpha), a protein pathway implicated in kidney cancer progression. The trial found the drug produced measurable and durable tumor responses among treated patients. Researchers, including those from the University of Miami Miller School of Medicine, characterized the results as confirming the clinical potential of this approach as a new treatment avenue for advanced kidney cancer. As a Phase 1 study, the results represent an early-stage signal, with the trajectory toward Phase 2 development still to be determined.